Catalyst Event
Sino Biopharmaceutical Ltd (1177) · Other
From Akros SCHK HK-U.S. Biotech Index (ASHUBIO)
5/11/2026, 12:00:00 AM
Announced an exclusive strategic collaboration with GSK to commercialize bepirovirsen in mainland China on 2026-05-11; analysts forecast high sales potential and a price impact of ≥10% forecasted.
Korean Translation
2026-05-11 중국 본토 내 베피로비르센 상용화를 위해 GSK와 독점적 전략적 협력을 발표함. 분석가들은 높은 매출 잠재력과 10% 이상의 주가 영향이 있을 것으로 전망됨.
Related Recent Events
3SBio Inc (1530) · Earnings Release
First half 2026 earnings results are expected to be released around August 26, 2026, expected. High importance is estimated due to the significant impact of previous earnings growth on stock volatility.
8/26/2026, 12:00:00 AM
3SBio Inc (1530) · Other
The ex-dividend date for the final cash dividend of HKD 0.25 per share for the fiscal year 2025 is July 21, 2026, scheduled.
7/21/2026, 12:00:00 AM
Sino Biopharmaceutical Ltd (1177) · Other
The ex-dividend date for the proposed final dividend of HKD 0.05 per share is 2026-06-24, which is estimated to have a price impact of ≥1% scheduled.
6/24/2026, 12:00:00 AM
Innovent Biologics Inc (1801) · Other
Innovent will present obesity pipeline data at the ADA Scientific Sessions on June 5-8, 2026; this low-impact event is scheduled
6/5/2026, 12:00:00 AM
Giant Biogene Holding Co Ltd (2367) · Other
Ex-dividend date of 2026-06-01 for final and special dividends, scheduled. (Estimated Low impact as dividend is standard).
6/1/2026, 12:00:00 AM
CSPC Pharmaceutical Group Ltd (1093) · Earnings Release
Q1 2026 earnings release scheduled. Analysts forecast revenue of 7.52B HKD. Estimated Medium importance as earnings results typically drive significant price movement scheduled.
5/27/2026, 12:00:00 AM